<DOC>
	<DOCNO>NCT02954354</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy single , oral dose S-033188 compare placebo measure time alleviation symptom patient uncomplicated influenza virus infection .</brief_summary>
	<brief_title>A Study S-033188 Compared With Placebo Oseltamivir Otherwise Healthy Patients With Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>1 . Patients able understand study comply study procedure , willing provide write informed consent/assent prior predose examination appropriately . As adolescent patient , inform consent/assent voluntary participation obtain accordance local requirement 2 . Male female patient age ≥ 12 ≤ 64 year time signing informed consent/assent form . 3 . Patients diagnosis influenza virus infection confirm follow : 1 . Fever ≥ 38ºC ( axillary ) predose examination &gt; 4 hour dose antipyretic take 2 . At least one follow general systemic symptom associate influenza present severity moderate great Headache Feverishness chill Muscle joint pain Fatigue 3 . At least one follow respiratory symptom associate influenza present severity moderate great Cough Sore throat Nasal congestion 4 . The time interval onset symptom predose examination 48 hour less . The onset symptom define either : 1 . Time first increase body temperature ( increase least 1ºC normal body temperature ) 2 . Time patient experience least one general respiratory symptom 5 . Women childbearing potential agree use highly effective method contraception 3 month first dose study drug 1 . Patients severe influenza virus infection require inpatient treatment . 2 . Patients age ≥ 20 year know allergy oseltamivir ( Tamiflu® ) . 3 . Patients follow risk factor 1 . Women pregnant within 2 week postpartum 2 . Residents longterm care facility ( eg , welfare facility elderly , nurse home ) 3 . Chronic respiratory disease include bronchial asthma 4 . Neurological neurodevelopmental disorder include disorder brain , spinal cord , peripheral nerve , muscle ( eg , cerebral palsy , epilepsy [ seizure disorder ] , stroke , intellectual disability , moderate severe developmental delay , muscular dystrophy , spinal cord injury ) 5 . Heart disease ( congenital heart disease , congestive heart failure , coronary artery disease ) , exclude hypertension without heartrelated symptom ) 6 . American Indians Alaskan native 7 . Blood disorder ( sickle cell disease ) 8 . Endocrine disorder ( include diabetes mellitus ) 9 . Kidney disorder 10 . Liver disorder 11 . Metabolic disorder 12 . Compromised immune system ( include patient receive immunosuppressant therapy , cancer human immunodeficiency virus [ HIV ] infection ) 13 . Morbid obesity ( body mass index [ BMI ] ≥ 40 ) 4 . Patients unable swallow tablet capsule . 5 . Patients previously receive S033188 . 6 . Patients weigh &lt; 40 kg 7 . Patients expose investigational drug within 30 day prior predose examination . 8 . Women breastfeed positive pregnancy test predose examination . The following female patient documentation either b need undergo pregnancy test predose examination : 1 . Postmenopausal ( define cessation regular menstrual period 2 year confirm folliclestimulating hormone test ) woman 2 . Women surgically sterile hysterectomy , bilateral oophorectomy , tubal ligation 9 . Patients concurrent infection require systemic antimicrobial and/or antiviral therapy predose examination . 10 . Patients receive peramivir , laninamivir , oseltamivir , zanamivir , rimantadine , umifenovir , amantadine within 30 day prior predose examination . 11 . Patients receive investigational monoclonal antibody viral disease last year . 12 . Patients severe underlying disease . 13 . Patients know creatinine clearance ≤ 60 mL/min . 14 . Patients , opinion investigator , would unlikely comply require study visit , selfassessments , intervention</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Flu</keyword>
	<keyword>S-033188</keyword>
	<keyword>Oseltamivir</keyword>
	<keyword>Tamiflu®</keyword>
</DOC>